Market Analysis Digital Therapeutics Growth Potential to 2027 | Page 2

Global Digital Therapeutics Market to 2027
www.theinsightpartners.com
The global digital therapeutics market is expected to reach US$ 8,941.1 Mn by 2025 from US$ 1,993.2 Mn in 2017. The
market is estimated to grow with a CAGR of 20.8% during the forecast period from 2018 to 2025.
North America is the largest geographic market and it is expected to be the largest revenue generator during the forecast
period, whereas the market is expected to witness growth at a significant rate in Asia Pacific (APAC) region during the
forecast period. Factors such as, increasing prevalence of the chronic diseases, acceptance of the digital health
platforms, developments performed by the market players in the countries such as India, China, Australia and others are
likely to propel growth of the market.
Market Insights
Rising prevalence of chronic diseases to boost market growth
Chronic diseases, including heart disease, stroke, diabetes, and obesity, are the leading causes of death in the world and
account for most of the nation’s health care costs. According to report of CDC, in 2018, approximately more than 9% of
the population has diabetes, which is the leading cause of kidney failure, lower-limb amputations in US. Moreover, the
data also suggests that 1.5 million Americans are diagnosed with diabetes every year in the US. Similar trends for high
presence of diabetes are prevalent around other geographies of the globe that include Asia Pacific, Europe, Middle East
and Africa. For instance, according to IDF Diabetes Atlas published by the International Diabetes Federation in 2017,
south-east Asia is home to approximately one-fifth (19%) of the total diabetes population worldwide. According to the
report of American College of Cardiology Foundation, in 2018, Coronary heart disease (CHD) was the leading cause of
deaths attributable to cardiovascular disease (CVD) in the US, which is followed by stroke (16.8%), high BP (9.4%), heart
failure (HF) (9.0%), and other CVDs (17.9%). By 2035, approximately 130 million adults in the US population are projected
to have some form of CVD. Thus, increasing geriatric population and related chronic diseases are expected to propel the
growth of global digital therapeutics market over the forecast years.
Get Sample PDF at https://www.theinsightpartners.com/sample/TIPHC00002236
Rising Pressure on Healthcare Providers to Reduce Healthcare Costs
Digital therapeutics help in reducing the costs associated with chronic diseases, by helping an individual or an insurance
provider to keep a track of one’s health status as well as track it with the help of digital means. As per American Diabetes
Association, the estimated costs of diagnosed diabetes have risen to $327 billion in 2017, including $237 billion in direct
medical costs and $90 billion in reduced productivity. This cost can be managed efficiently by including digital
therapeutics that are offered by providers to help manage diabetes, can help patients get assistance with disease
management and overcome the logistical challenges uncovered by the investigators.
Application Insights
The digital therapeutics market by application is segmented into diabetes, cardiovascular diseases, and central nervous
system diseases, respiratory diseases, smoking cessation, musculoskeletal diseases and others. In 2017, the diabetes
segment held a largest market share of 26.6% of the digital therapeutics, by application. This segment is also expected
to dominate the market in 2025. The growth of the market is primarily attributed to the rising prevalence of diabetes
2